相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1844
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Long-term exposure to fine particulate matter and nitrogen dioxide at levels below current regulatory limits is associated with advanced coronary artery disease, according to a study of over 11,000 adults in Toronto. - Women showed significantly greater odds of serious artery narrowing with higher pollution exposure, while the association in men was not statistically significant. - A separate review of 95 global studies found that 67% showed significant links between low-level PM2.5 exposure and cardiovascular harm, with vulnerable populations at heightened risk. - Researchers suggest that stricter air quality standards could meaningfully protect cardiovascular health, as no clear "safe" threshold was identified.
- MMJ BioPharma Cultivation has been trapped in a seven-year regulatory paradox, unable to produce pharmaceutical-grade cannabis for FDA-approved clinical trials despite passing inspections and receiving Orphan Drug Designations. - The DEA requires companies to present "bona fide supply agreements" before issuing bulk manufacturing registrations, but federal law prohibits signing such agreements without the license first. - The U.S. Department of Veterans Affairs has applied for DEA approval to import marijuana extracts from abroad for PTSD and chronic pain research, highlighting the agency's contradictory approach to domestic versus foreign cannabis supply. - The regulatory obstruction has forced legitimate pharmaceutical research overseas while blocking American companies from producing cannabis for neurological conditions like Huntington's disease and multiple sclerosis.
- University of Mississippi researchers developed sugar-coated nanoparticles that exploit cancer cells' glucose transporter overexpression to deliver chemotherapy drugs more effectively to triple-negative breast cancer. - The innovative approach could reduce side effects by selectively targeting cancer cells while sparing healthy tissue, addressing a critical need for this aggressive cancer subtype. - Mississippi shows particularly high rates of triple-negative breast cancer, with 37% of breast cancer patients treated at the University of Mississippi Medical Center between 2016-2023 having this subtype. - The delivery mechanism may have broader applications for other diseases that overexpress glucose transporters, including colon cancer, brain cancer, and fatty liver disease.
